Clinical Trials Browser

Adenocarcinoma, Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Rectal Diseases, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01396382 2016-03-29

68Ga

Phase 2 Completed

97 enrolled 4 charts

EndocrineNET

Apudoma, Carcinoid Tumor, Adenoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase 2 Completed

43 enrolled 9 charts

Endocrine

Carcinoma, Neuroendocrine

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Phase 2 Terminated

2 enrolled 4 charts

EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00607113 2013-07-18

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

Phase 2 Completed

41 enrolled 6 charts

Endocrine

Carcinoma, Neuroendocrine

Clinical Trials

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

68Ga

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma